Results 21 to 30 of about 280,907 (304)

Endothelins and liver cirrhosis

Portal Hypertension & Cirrhosis, 2022
Endothelins are a family of 21‐amino acid oligopeptides, called endothelin‐1 (ET‐1), endothelin‐2 (ET‐2), and endothelin 3 (ET‐3). Endothelins act on hepatocytes, liver endothelial cells, and Kupffer cells in a paracrine or autocrine manner through two G
Necati Örmeci
doaj   +1 more source

Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going

Biology, 2022
Endothelin was first discovered more than 30 years ago as a potent vasoconstrictor. In subsequent years, three isoforms, two canonical receptors, and two converting enzymes were identified, and their basic functions were elucidated by numerous ...
Andreas Haryono, Risa Ramadhiani, Gusty Rizky Teguh Ryanto, Noriaki Emoto   +3 more
doaj   +1 more source

Endothelin Receptors and Their Antagonists

Seminars in Nephrology, 2015
All three members of the endothelin (ET) family of peptides, ET-1, ET-2, and ET-3, are expressed in the human kidney, with ET-1 being the predominant isoform. ET-1 and ET-2 bind to two G-protein-coupled receptors, ETA and ETB, whereas at physiological concentrations ET-3 has little affinity for the ET(A) receptor.
Maguire, Janet J, Davenport, Anthony P
openaire   +4 more sources

Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?

BMC Cancer, 2018
Background Glioblastoma (GBM) is the most common malignant brain tumor with median survival of 12-15 months. Owing to uncertainty in clinical outcome, additional prognostic marker(s) apart from existing markers are needed.
Suhas Vasaikar, Giorgos Tsipras, Natalia Landázuri, Helena Costa, Vanessa Wilhelmi, Patrick Scicluna, Huanhuan L. Cui, Abdul-Aleem Mohammad, Belghis Davoudi, Mingmei Shang, Sharan Ananthaseshan, Klas Strååt, Giuseppe Stragliotto, Afsar Rahbar, Kum Thong Wong, Jesper Tegner, Koon-Chu Yaiw, Cecilia Söderberg-Naucler   +17 more
doaj   +1 more source

CLINICAL CASE OF COMBINATION THERAPY INCLUDING AMBRIZENTAN IN THE PATIENT WITH SEVERE IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION

Евразийский Кардиологический Журнал, 2017
Idiopathic pulmonary hypertension (IPAH) is a rare cardiovascular disease of unknown etiology, but the most common form of pulmonary arterial hypertension, defined as mean pulmonary arterial pressure >25 mmHg and pulmonary vascular resistance >3 ...
G. A. Movsisyan, O. A. Arkhipova, I. Z. Korobkova, Yu. G. Matchin, M. A. Saidova, T. V. Martynyuk, I. Ye. Chazova   +6 more
doaj   +1 more source

The use of Macitentan in Fontan circulation: a case report

BMC Cardiovascular Disorders, 2017
Background The Fontan circulation, a result of a palliative procedure in patients with single systemic ventricles, is defined by chronically elevated pulmonary vascular resistance.
Polyvios Demetriades, Amir Aziz, Robin Condliffe, Sarah E. Bowater, Paul F. Clift   +4 more
doaj   +1 more source

Sitaxsentan-Induced Acute Severe Hepatitis Treated with Glucocorticoid Therapy

Canadian Respiratory Journal, 2012
Endothelin receptor antagonists are commonly used in the treatment of pulmonary hypertension. Sitaxsentan, a selective endothelin A receptor blocker, induces a mild transaminitis in approximately 3% to 5% of patients, but rarely an acute severe hepatitis.
Marcus W Chin, Robert D Levy, Eric M Yoshida, Michael F Byrne   +3 more
doaj   +1 more source

Portopulmonary hypertension practice patterns after liver transplantation

Liver Transplantation, EarlyView., 2022
Abstract Portopulmonary hypertension (POPH) is a type of pulmonary arterial hypertension occurring exclusively in those with portal hypertensive liver disease. Liver transplantation (LT) can significantly improve outcomes. Current guidelines counsel against immediate adjustments to targeted therapy after LT and suggest routine echocardiography as ...
Arun Jose, Elizabeth J. Kopras, Shimul A. Shah, Jean M. Elwing   +3 more
wiley   +1 more source

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)

Pulmonary Circulation, 2020
Many patients with pulmonary arterial hypertension do not achieve treatment goals with monotherapy, and therefore combination therapy is becoming the standard of care.
Hossein-Ardeschir Ghofrani, Ekkehard Grünig, Pavel Jansa, David Langleben, Stephan Rosenkranz, Ioana R. Preston, Franck Rahaghi, Namita Sood, Dennis Busse, Christian Meier, Marc Humbert   +10 more
doaj   +1 more source

Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.

Journal of Medicinal Chemistry, 2016
The endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for therapeutic intervention in human diseases. Endothelin-receptor antagonists are in clinical use to treat pulmonary arterial hypertension and have been under ...
J. Aubert, L. Juillerat-Jeanneret
semanticscholar   +1 more source